Phosphorylation of AKT pathway proteins is not predictive of benefit of taxane therapy in early breast cancer

Breast Cancer Research and Treatment

Volumn 138, Issue 3, 2013, Pages 773-781

  Bartlett, John M S ^a,b   A'Hern, Roger ^c   Piper, Tammy ^b   Ellis, Ian O ^d   Dowsett, Mitch ^e   Mallon, Elizabeth A ^f   Cameron, David A ^g   Johnston, Stephen ^h   Bliss, Judith M ^c   Ellis, Paul ⁱ   Barrett Lee, Peter J ^j  

^a ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^e INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^f WESTERN INFIRMARY   (United Kingdom)

^g WESTERN GENERAL HOSPITAL   (United Kingdom)

^h ROYAL MARSDEN HOSPITAL   (United Kingdom)

ⁱ GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^j VELINDRE CANCER CENTRE   (United Kingdom)

more..

Author keywords

AKT; Biomarkers; Breast cancer; Clinical trial; Pathology; Taxanes

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; PROTEIN KINASE B; PROTEIN P70; PROTEIN P90; PROTEIN PS6; TUMOR MARKER; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADULT; ARTICLE; BREAST CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; EARLY CANCER; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADULT; ANTHRACYCLINES; BIOLOGICAL MARKERS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; PHOSPHORYLATION; PREDICTIVE VALUE OF TESTS; PROTO-ONCOGENE PROTEINS C-AKT; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; RIBOSOMAL PROTEIN S6 KINASES, 90-KDA; TAXOIDS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME;

EID: 84877798243     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2489-y     Document Type: Article

References (40)

1. Peto R (2002) Update of the worldwide evidence on the adjuvant treatment of breast cancer. Eur J Cancer 38:E11
2. Ellis P, Barrett-Lee P, Johnson L et al (2009) Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. Lancet 373(9676):1681-1692
3. Hayes DF, Thor AD, Dressler LG et al (2007) HER2 and response to paclitaxel in node-positive breast cancer. New Engl J Med 357(15):1496-1506
4. Yang SX, Costantino JP, Kim C et al (2010) Akt Phosphorylation at Ser473 Predicts Benefit of Paclitaxel Chemotherapy in Node-Positive Breast Cancer. J Clin Oncol 28(18):2974-2981
5. Hu LM, Hofmann J, Lu YL, Mills GB, Jaffe RB (2002) Inhibition of phosphatidylinositol 3 '-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res 62(4):1087-1092
6. Calastretti A, Bevilacqua A, Ceriani C et al (2001) Damaged microtubules can inactivate BCL-2 by means of the mTOR kinase. Oncogene 20(43):6172-6180
7. Calastretti A, Rancati F, Vigano S et al (1999) Taxol-induced apoptosis and BCL-2 degradation inhibited by rapamycin. Clin Cancer Res 5:3814S
8. Page C, Lin HJ, Jin Y et al (2000) Overexpression of Akt/AKT can modulate chemotherapy-induced apoptosis. Anticancer Res 20(1A):407-416
9. Dillon RL, Marcotte R, Hennessy BT, Woodgett JR, Mills GB, Muller WJ (2009) Akt1 and Akt2 play distinct roles in the initiation and metastatic phases of mammary tumor progression. Cancer Res 69(12):5057-5064
10. Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B (2010) The emerging mechanisms of isoform-specific PI3 K signalling. Nat Rev Mol Cell Biol 11(5):329-341
11. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB (2005) Exploiting the PI3 K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 4(12):988-1004
12. Kirkegaard T, Witton CJ, Edwards J et al (2010) Molecular alterations in AKT1, AKT2 and AKT3 detected in breast and prostatic cancer by FISH. Histopathology 56(2):203-211
13. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A et al (2008) Integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 68(15):6084-6091
14. Ellis MJ, Tao Y, Lin L et al (2006) High nuclear p27(kip1) levels predicts sensitivity to neoadjuvant letrozole in ER plus breast cancer independent of pAKT levels, PIK3CA mutation status and cell cycle effects: a potential role for p27(kip1) in predicting enhanced autophagocytosis in response to aromatase inhibitor therapy. Breast Cancer Res Treat 100:S187
15. Tokunaga E, Kimura Y, Oki E et al (2006) Akt is frequently activated in HER2/neu-positive breast cancers and associated with poor prognosis among hormone-treated patients. Int J Cancer 118(2):284-289
16. Panigrahi AR, Pinder SE, Chan SY, Paish EC, Robertson JFR, Ellis IO (2004) The role of PTEN and its signalling pathways, including AKT, in breast cancer; an assessment of relationships with other prognostic factors and with outcome. J Pathol 204(1):93-100
17. MacKeigan JP, Taxman DJ, Hunter D, Earp HS, Graves LM, Ting JPY (2002) Inactivation of the antiapoptotic phosphatidylinositol 3- kinase-Akt pathway by the combined treatment of taxol and mitogen-activated protein kinase kinase inhibition. Clin Cancer Res 8(7):2091-2099
18. Ling X, Bernacki RJ, Brattain MG, Li FZ (2004) Induction of survivin expression by taxol (paclitaxel) is an early event, which is independent of taxol-mediated G(2)/M arrest. J Biol Chem 279(15):15196-15203
19. Le XF, Hittelman WN, Liu JX et al (2003) Paclitaxel induces inactivation of p70 S6 kinase and phosphorylation of Thr(421) and Ser(424) via multiple signaling pathways in mitosis. Oncogene 22(4):484-497
20. Workman P, Clarke PA, Raynaud FI, van Montfort RLM (2010) Drugging the PI3 kinome: from chemical tools to drugs in the clinic. Cancer Res 70(6):2146-2157
21. Copp J, Manning G, Hunter T (2009) TORC-specific phosphorylation of mammalian target of rapamycin (mTOR): phospho-Ser2481 is a marker for intact mTOR signaling complex 2. Cancer Res 69(5):1821-1827
22. Sabine VS, Sims AH, Macaskill EJ et al (2009) Transcriptional profiling of patient-matched ER-positive breast cancer tissue from post-menopausal women treated with neoadjuvant RAD001. Cancer Res 69(2):166S-167S
23. Kirkegaard T, Witton CJ, McGlynn LM et al (2005) AKT activation predicts outcome in breast cancer patients treated with tamoxifen. J Pathol 207(2):139-146
24. Ellis IO, Dowsett M, Bartlett J et al (2000) Recommendations for HER2 testing in the UK. J Clin Pathol 53(12):890-892
25. Dowsett M, Bartlett J, Ellis IO et al (2003) Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J Pathol 199(4):418-423
26. Ellis IO, Bartlett J, Dowsett M et al (2004) Updated recommendations for HER2 testing in the UK. J Clin Pathol 57(3):233-237
27. Walker RA, Bartlett JMS, Dowsett M et al (2008) HER2 testing in the UK: further update to recommendations. J Clin Pathol 61(7):818-824
28. Bartlett JMS, Ellis IO, Dowsett M et al (2007) Human Epidermal Growth Factor Receptor 2 Status Correlates With Lymph Node Involvement in Patients With Estrogen Receptor (ER) Negative, but With Grade in Those With ER-Positive Early-Stage Breast Cancer Suitable for Cytotoxic Chemotherapy. J Clin Oncol 25(28):4423-4430
29. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2005) REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 93(4):387-391
30. Kirkegaard T, Edwards J, Tovey S et al (2006) Observer variation in immunohistochemical analysis of protein expression, time for a change? Histopathology 48(7):787-794
31. Royston P, Sauerbrei W (2008) Multivariable model-building. A pragmatic approach to regression analysis based on fractional polynomials for modeling continuous variables
32. Sarbassov DD, Ali SM, Sengupta S et al (2006) Prolonged rapamycin treatment inhibits mTORC2 assembly and AKT/PKB. Mol Cell 22(2):159-168
33. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005) Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex. Science 307(5712):1098-1101
34. Buttrick GJ, Wakefield JG (2008) PI3-K and GSK-3 AKT-ing together with microtubules. Cell Cycle 7(17):2621-2625
35. Pinhel I, MacNeill F, Hills M et al (2010) Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer. Breast Cancer Res 12(5):R76
36. Generali D, Fox SB, Brizzi MP et al (2008) Down-regulation of phosphatidylinositol 3 '-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer. Clin Cancer Res 14(9):2673-2680
37. Bandyopadhyay S, Sengupta TK, Fernandes DJ, Spicer EK (2003) Taxol- and okadaic acid-induced destabilization of bcl-2 mRNA is associated with decreased binding of proteins to a bcl-2 instability element. Biochem Pharmacol 66(7):1151-1162
38. Montgomery RB, Guzman J, O'Rourke DM, Stahl WL (2000) Expression of oncogenic epidermal growth factor receptor family kinases induces paclitaxel resistance and alters beta-tubulin isotype expression. J Biol Chem 275(23):17358-17363
39. Kavallaris M, Annereau JP, Barret JM (2008) Potential mechanisms of resistance to microtubule inhibitors. Semin Oncol 35(3):S22-S27
40. Chien AJ, Moasser MM (2008) Cellular mechanisms of resistance to anthracyclines and taxanes in cancer: intrinsic and acquired. Semin Oncol 35(2):S1-S14